As of mid-2026, the Reckitt Benckiser share price (LSE: RKT) is trading around the 4,680p mark, representing a significant decline of over 20% from its 52-week high of 6,522.92p. For value investors, contrarians, and dividend-growth seekers, this sharp discount raises a critical question: is this FTSE 100 consumer goods titan a deeply undervalued bargain, or is it a classic value trap weighed down by existential legal liabilities? This comprehensive analysis explores the complex web of factors currently steering the Reckitt Benckiser share price, from its operational turnaround and massive asset sales to the Danone acquisition rumors and the shadow of the ongoing US baby formula litigation.

To understand the company's trajectory, one must look beyond the immediate stock ticker. Over the past two years, Reckitt has undergone a massive structural shift, moving away from home care products to focus on its high-margin "Powerbrands" in health and hygiene. However, this strategic transformation is playing out against a backdrop of complex US multi-district product liability lawsuits and localized volume headwinds. Understanding the potential direction of the stock requires a balanced assessment of these shifting operational realities, corporate divestitures, and unresolved legal outcomes.

The Macro Dynamics of the Reckitt Benckiser Share Price

To unpack the performance of the Reckitt Benckiser share price, we must first address the immediate macroeconomic and operational pressures that have triggered the stock's retreat. While Reckitt's core business remains a highly cash-generative machine, several near-term headwinds have combined to sour investor sentiment.

First and foremost is the impact of seasonal volatility on the company’s consumer health portfolio. In late April 2026, Reckitt reported a sluggish start to the financial year, with first-quarter revenues missing some analyst expectations. The culprit was a historically mild cold and flu season across Europe and North America. Brands like Mucinex (respiratory relief), Strepsils (throat lozenges), and Nurofen (pain relief) are massive profit drivers during peak winter months. When mild weather dampens seasonal illness, the sudden reduction in high-margin OTC volumes flows directly to the bottom line, sparking sharp, short-term drops in the share price.

Second, input cost volatility remains an ongoing concern. Throughout late 2025 and into 2026, global oil prices have flirted with the $100 per barrel mark. Reckitt’s management has noted that if crude prices remain elevated, the company faces an incremental £130 million to £150 million increase in its input cost base, specifically affecting plastic packaging, petrochemical raw materials, and global logistics. While the company has demonstrated solid pricing power over the years to combat inflation, pushing further price hikes onto economically strained consumers carries the risk of volume erosion, especially as private-label alternatives grow more competitive.

Despite these near-term pressures, Reckitt's underlying operational foundation remains remarkably robust. For the full year ended December 31, 2025, Reckitt reported a dramatic 83% jump in pretax profit to £3.84 billion (up from £2.10 billion in 2024). This surge was primarily driven by restructuring efficiencies and the successful completion of major asset sales, proving that the "Core Reckitt" portfolio is structurally healthier than the headline share price suggests.

The Turnaround Strategy: Divesting Non-Core Assets and Capital Return

In July 2024, Reckitt’s management announced a sweeping strategic overhaul designed to reshape the business into a pure-play consumer health and hygiene powerhouse. This involved separating the company's assets into "Core Reckitt"—home to high-growth, high-margin Powerbrands like Dettol, Lysol, Finish, Durex, Gaviscon, and Nurofen—and non-core divisions slated for divestment.

The most significant milestone of this strategy was finalized on December 31, 2025, with the sale of the "Essential Home" portfolio. This segment, which included household names like Air Wick, Calgon, Mortein, and Cillit Bang, was sold to private equity for a total consideration of $4.8 billion. While these brands are globally recognized, their lower growth profile and capital-intensive nature dragged down the group’s overall operating margins.

By shedding the Essential Home division, Reckitt successfully streamlined its operations and unlocked massive liquidity. The cash proceeds were immediately put to work for shareholders:

• The Special Dividend: In February 2026, Reckitt distributed approximately £1.6 billion to its shareholders in the form of a massive special dividend, which equated to a significant cash return per share.
• Share Buybacks: The company completed the second tranche of its £1 billion share buyback program in January 2026, reducing the outstanding share count and providing a technical floor for the stock.
• Dividend Hikes: Alongside the special dividend, the Board proposed a final 2025 ordinary dividend of 127.8p, bringing the full-year 2025 ordinary dividend to 212.2p (up 5.0% from 202.1p in 2024).

By narrowing its scope, the company has managed to reduce fixed costs significantly. Under its "Fuel for Growth" program, Reckitt achieved a 150-basis-point reduction in fixed costs, bringing them down to 19.4% of net revenue in 2025. This freed-up capital has been aggressively redeployed into Brand Equity Investment (BEI), which rose to 14.6% of net revenue. The thesis is clear: by spending more on marketing and research and development for its core medical and material science brands, Reckitt can drive premiumization and secure long-term market leadership in expanding sectors like self-care and germ protection.

The Danone Deal: Can Reckitt Successfully Divest Mead Johnson?

While the Essential Home sale represents a major victory, the second pillar of Reckitt’s restructuring—the strategic exit from its infant formula business, Mead Johnson Nutrition—presents a far more complex hurdle.

Reckitt famously acquired Mead Johnson (maker of Enfamil and Nutramigen) in 2017 for $16.6 billion. The transaction is widely regarded by analysts as a strategic misstep, as it saddled the parent company with high debt levels and structural declines in the infant formula sector, primarily due to falling birth rates in key markets like China. In July 2024, Reckitt formally classified the Mead Johnson business as non-core, initiating a process to seek all strategic options, including a full sale or spin-off.

In April 2026, the market received a major jolt when reports emerged that French dairy and nutrition giant Danone is "discreetly exploring" a buyout of Mead Johnson. Danone has reportedly engaged New York-based investment bank Centerview Partners to assess the feasibility of an acquisition. From a strategic perspective, the match has clear merit. Danone is already a dominant global player in early-life nutrition, with its Specialised Nutrition division generating over €9.3 billion in 2025. Acquiring Mead Johnson would instantly vault Danone into a market-leading position in North America, filling a major geographic gap in its portfolio.

However, the primary roadblock to any potential sale is the staggering litigation risk associated with Mead Johnson. Financial analysts have raised serious questions about how a deal would be structured. Would Danone be willing to assume the potentially multi-billion-dollar liabilities of the US infant formula lawsuits, or will Reckitt be forced to ring-fence and retain those legal liabilities to facilitate an exit? If Reckitt can successfully negotiate a clean break or sell the unit at a reasonable valuation, it would remove a massive operational distraction and likely trigger a major re-rating of the Reckitt Benckiser share price.

The Legal Overhang: Understanding the US NEC Baby Formula Lawsuits

To fully appreciate why the Reckitt Benckiser share price remains depressed despite strong underlying earnings, one must understand the legal battleground of the Necrotizing Enterocolitis (NEC) baby formula litigation in the United States.

Mead Johnson (owned by Reckitt) and its primary competitor, Abbott Laboratories (maker of Similac), are currently facing approximately 800 active lawsuits consolidated in a federal multi-district litigation (MDL 3026) in the Northern District of Illinois, overseen by US District Judge Rebecca Pallmeyer. Hundreds of additional cases are also moving through state courts.

What are the lawsuits about?

The plaintiffs are parents of premature infants who developed necrotizing enterocolitis (NEC)—a severe, often fatal gastrointestinal condition where intestinal tissue becomes inflamed and dies. The lawsuits allege that cow’s-milk-based preterm infant formulas, such as Enfamil and Similac, dramatically increase the risk of NEC in premature babies compared to human breast milk. The core of the legal argument is product liability and failure to warn: plaintiffs claim that Mead Johnson and Abbott knew of this scientific risk but deliberately failed to include clear warnings on their packaging or instruct doctors and parents on the danger.

What are the key verdicts so far?

Early trials in state courts have resulted in highly volatile, high-stakes verdicts that have severely shaken investor confidence:

• March 2024 (Illinois): A state court jury ordered Mead Johnson to pay $60 million in damages to a mother whose baby died of NEC after being fed Enfamil. This verdict was the initial catalyst that sent the Reckitt Benckiser share price tumbling.
• July 2024 (Missouri): A state court jury hit competitor Abbott Laboratories with a staggering $495 million verdict ($95 million compensatory, $400 million punitive). Crucially, in May 2026, a Missouri appeals court upheld this full $495 million verdict, rejecting Abbott's legal appeals.
• April 2026 (Illinois): A Chicago state court jury ordered Abbott to pay $70 million in damages to four families, further demonstrating that juries are highly sympathetic to the plaintiffs in these cases.

The "Learned Intermediary" Defeat

A critical legal setback occurred in May 2026 during Abbott's appeal. The manufacturers argued that they should be protected by the "learned intermediary doctrine." This legal defense asserts that because preterm infant formula is a highly specialized product administered by neonatologists in neonatal intensive care units (NICUs), the manufacturer’s sole duty is to warn the prescribing doctors, not the parents. However, the appellate court firmly rejected this argument, ruling that preterm baby formula is classified as a food, not a prescription drug or medical device. Consequently, the manufacturers cannot shield themselves behind the hospital staff. This ruling has severe negative implications for Mead Johnson, as it establishes a highly challenging precedent for the remaining cases.

Upcoming July/August 2026 Bellwether Trials

While state court trials have proceeded, the federal MDL families are still waiting for their turn. In May 2026, the federal judge denied Mead Johnson’s motion for summary judgment in the first scheduled federal bellwether case, Inman v. Mead Johnson. This case is officially headed to a jury trial in July/August 2026.

Because bellwether trials serve as test cases to gauge how juries react to evidence, the outcome of the Inman trial will be an incredibly powerful driver of the Reckitt Benckiser share price. A defense win for Mead Johnson could signal that the litigation risk is manageable, potentially triggering a massive relief rally. Conversely, another multi-million-dollar plaintiff verdict will likely depress the share price further and push Reckitt toward a global settlement that could cost the company billions.

Financial Metrics & Valuation: Value Play or Yield Trap?

To evaluate the investment thesis for Reckitt Benckiser, we must look at the hard financial numbers. The table below outlines the key financial indicators for the company as of mid-2026:

At a trailing Price-to-Earnings (P/E) ratio of under 10, Reckitt Benckiser is trading at a historic discount compared to both its ten-year historical average (which typically hovered between 16 and 20) and its peer group. For comparison, consumer defensives like Unilever typically trade at P/E multiples of 16 to 18. This steep discount is a direct reflection of the "litigation discount" applied by the market due to the NEC lawsuits.

However, from a cash flow perspective, the business is highly robust. Free cash flow generation for FY 2025 came in at approximately £1.7 billion, even after accounting for £179 million in one-off restructuring and transformation costs. Thanks to the cash proceeds of the Essential Home sale, Reckitt has successfully deleveraged its balance sheet, reducing its Net Debt to Adjusted EBITDA ratio from 2.0x to a very comfortable 1.6x.

With an ordinary dividend yield of over 4.5%—complemented by the massive capital return from the special dividend—income investors are being paid handsomely to wait. If the company can successfully manage the NEC litigation through a capped settlement or if Danone acquires Mead Johnson while absorbing a portion of the risk, the discount on the share price could rapidly evaporate. However, if the federal bellwether trials starting in July 2026 go poorly, the potential liabilities could threaten capital allocation, making the current high yield look more like a classic yield trap.

Frequently Asked Questions (FAQ)

Why is the Reckitt Benckiser share price down in 2026?

The share price is primarily depressed due to two main factors: the overhang of the US necrotizing enterocolitis (NEC) infant formula lawsuits involving its Mead Johnson division, and near-term volume softness in Q1 2026 resulting from an unusually mild winter cold and flu season, which impacted sales of over-the-counter health brands like Mucinex and Strepsils.

Is Reckitt Benckiser selling its infant formula business?

Yes, Reckitt formally classified its Mead Johnson Nutrition division as "non-core" in July 2024. In April 2026, reports emerged that French consumer giant Danone is actively and discreetly exploring a buyout of the business, utilizing Centerview Partners as financial advisers. However, structuring the deal around the outstanding US litigation remains a major hurdle.

What is the current dividend yield of Reckitt Benckiser?

Based on a share price of ~4,680p and the full-year 2025 ordinary dividend of 212.2p, the stock offers a highly attractive ordinary dividend yield of approximately 4.5% to 5.0%. This does not include the massive £1.6 billion special dividend paid to shareholders in February 2026 following the sale of its Essential Home portfolio.

When is the next major Mead Johnson lawsuit trial?

Following the denial of Mead Johnson's summary judgment motion in May 2026, the first highly anticipated federal bellwether trial in the multi-district litigation (Inman v. Mead Johnson) is scheduled to begin in July/August 2026. The outcome of this trial will be a major market-moving event for the stock.

Conclusion: The Verdict on Reckitt Benckiser

The Reckitt Benckiser share price in mid-2026 represents a classic high-risk, high-reward scenario. On one hand, the operational turnaround is delivering tangible results. The successful sale of the Essential Home division has left the company with a stronger balance sheet, a leaner operating model, and a highly focused portfolio of high-margin health and hygiene Powerbrands. The massive cash return to shareholders via buybacks, ordinary dividend growth, and the February 2026 special dividend highlights a management team highly committed to shareholder value.

On the other hand, the legal overhang of the Mead Johnson NEC litigation is an undeniable, binary risk. The upcoming federal bellwether trial in July/August 2026 is the ultimate pivot point. Investors looking for defensive, low-volatility income may want to stay on the sidelines until there is greater clarity on the potential liability cap. However, for risk-tolerant value investors, the current sub-10 P/E valuation and a 5% dividend yield offer an incredibly compelling entry point into a restructured consumer defensive giant that is slowly but surely returning to its pure-play roots.